Sanofi: Press Releases, Tuesday, December 10, 2019

Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease Sutimlimab, a novel investigational C1s inhibitor, has the potential to be the first approved treatment for cold agglutinin disease, a serious, chronic, rare blood disorder Results met the primary and secondary endpoints and demonstrated rapid inhibition of hemolysis and clinically significant improvements in anemia...

READ MORE Sanofi: Press Releases, Tuesday, December 10, 2019

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis TOKYO, Nov. 27, 2020 /PRNewswire[1]/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,...

READ MORE Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

VIFOR PHARMA PRESS RELEASE 2018 IRON DEFICIENCY DAY

VIFOR PHARMA PRESS RELEASE 2018 IRON DEFICIENCY DAY This year’s Iron Deficiency Day (26 November 2018) aims to raise awareness of the serious public health problems posed by iron deficiency and iron deficiency anaemia and highlight the negative impact the condition can have on its sufferers.1 Iron deficiency is present in one-third of the world’s population.2 It is most prevalent...

READ MORE VIFOR PHARMA PRESS RELEASE 2018 IRON DEFICIENCY DAY

GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease

For media and investors only Issued: London, UK Approval marks a significant step in GSK’s global efforts to help patients with anaemia due to chronic kidney disease (CKD). GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the approval of a Japanese New Drug Application (JNDA) by the Ministry of Health, Labour and Welfare for Duvroq (daprodustat) tablets, an oral hypoxia-inducible factor prolyl...

READ MORE GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease

Generated by Feedzy